I spent 45 minutes with Gerald at Table 2. I am just going to give a couple highlights tonight and then I'll make more comments tomorrow. (I've got to eat and get ready for "24")
At "Table 2" Gerald told my son and I that they had basically "identified their LymPro Partner." I'm sure final details are still being worked out, but I think it's a done deal. Gerald seemed very confident about that. And, Gerald said he would be releasing LymPro sensitivity and specificity data at the Copenhagen Conference. Copenhagen in mid July is going to be LymPro's introduction to the world! Another thing he said during the presentation was that the additional rights they just purchased on LymPro are going to help them increase their accuracy. So instead of being just above 90% accurate, they are going to get even better! (A nail in the coffin for future competitors to LymPro!) He said they are talking to Pharmas now that are doing AD clinical trials so they can put together "Revenue Guidance" after Copenhagen and have it be
meaningful. I have zero doubt that LymPro will commercialize by September or October (November at latest)
Regarding MANF, Gerald said we are still waiting for Wolframs data and that if it is strong enough, Wolframs could replace Retinitis as their lead indication. Also, he said they were conservative on the CC regarding getting orphan drug indications going. They said early 2015....today Gerald told me they are hopeful in getting the designations much much sooner!! (That is how Gerald felt MANF could help our Market Cap in near future) I probed him about Dr. Urano and a MANF/Diabetes Partnership in near future. He wouldn't comment other than to laugh. The same was true regarding an Eltoprazine Partner; laughter.
The Geneva office is just an office in Switzerland today, but the word "affiliate" he said was Dr. Lowe's choice. Gerald confirmed it could grow into something more. Geneva is a good place to be for many reasons! I was very pleased today. 24 is starting soon, ciao.
